Diagnosis of Exclusion : A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis

Abstract EN

Importance.

Medication-induced eosinophilia is an acknowledged, often self-limiting occurrence.

Glatiramer acetate, a biologic injection used in the management of relapsing-remitting multiple sclerosis, is widely regarded as a safe and effective medication and lists eosinophilia as an infrequent side effect in its package insert.

Contrary to reports of transient, benign drug-induced eosinophilia, we describe a case of probable glatiramer acetate-induced eosinophilia that ultimately culminated in respiratory distress, shock, and eosinophilic myocarditis.

Observations.

A 59-year-old female was admitted to the hospital after routine outpatient labs revealed leukocytosis (43,000 cells/mm3) with pronounced hypereosinophilia (63%).

This patient had been using glatiramer acetate without complication for over 10 years prior to admission.

Leukocytosis and hypereosinophilia persisted as a myriad of diagnostic evaluations returned negative, ultimately leading to respiratory depression, shock, and myocarditis.

Glatiramer acetate was held for the first time on day 6 of the hospital stay with subsequent resolution of leukocytosis, hypereosinophilia, respiratory distress, and shock.

Conclusions and Relevance.

Glatiramer acetate was probably the cause of this observed hypereosinophilia and the resulting complications.

Reports of glatiramer-induced eosinophilia are rare, and few case reports regarding medication-induced hypereosinophilia describe the severe systemic manifestations seen in this patient.